Product
TransCon CNP Placebo
1 clinical trial
1 indication
Indication
AchondroplasiaClinical trial
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2022-09-27